• BeOne Medicines AG ONC.OQ reported quarterly adjusted earnings of $1.09​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.15. The mean expectation of thirteen analysts for the quarter was for earnings of 78 cents per share. Wall Street expected results to range from 44 cents to $1.66 per share.

• Revenue rose 41% to $1.41 billion from a year ago; analysts expected $1.36 billion.

• BeOne Medicines AG's reported EPS for the quarter was $1.09​.

• The company reported quarterly net income of $124.84 million.

• BeOne Medicines AG shares had fallen by 5.7% this quarter and gained 74.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 29.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for BeOne Medicines AG is $373.00, about 13.8% above its last closing price of $321.39

This summary was machine generated from LSEG data November 6 at 11:50 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)